Accessibility StatementSkip Navigation Significant progress on multiple fronts – obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement of NYSE American trading PRINCETON, N.J., Nov. 13, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in- class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system, today announced financial results ...